Tuhura Biosciences releases corporate deck outlining strategy to tackle cancer immunotherapy resistance
HURA•Corporate deck highlights clinical and funding plans
Tuhura Biosciences highlighted a Phase 3 accelerated-approval study of IFx-2.0 with pembrolizumab in first-line metastatic Merkel cell carcinoma.
The trial targets about 118 patients in a 1:1 placebo injection-controlled design, with top-line data expected in the second half of 2027.
The program operates under an FDA Special Protocol Assessment, and a confirmatory trial is not expected to be required.
The company also said VISTA inhibitor TBS-2025 is planned to enter a Phase 1b/2 trial in relapsed or refractory mutNPM1 acute myeloid leukemia in the second half of 2026, with preliminary data targeted for the first half of 2027.
Tuhura cited a $50 million credit facility and royalty transaction as non-equity funding, with runway projected through the first quarter of 2028.
